BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 12722678)

  • 21. Gemcitabine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma.
    Yamagishi Y; Higuchi H; Izumiya M; Sakai G; Iizuka H; Nakamura S; Adachi M; Hozawa S; Takaishi H; Hibi T
    J Gastroenterol; 2010 Nov; 45(11):1146-54. PubMed ID: 20549255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Multi-center trial of gemcitabine for 49 patients with advanced pancreatic cancer].
    Sumii T; Funakoshi A; Ito T; Mizumoto K; Tanaka M; Migita Y; Sakai T; Shinozaki H; Yamaguchi H; Niyahara T; Muranaka T; Eriguchi N; Ueki T;
    Gan To Kagaku Ryoho; 2003 Jul; 30(7):971-6. PubMed ID: 12894712
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Gemcitabine therapy for unresectable pancreatic cancer in elderly patients].
    Katakura Y; Nakahara K; Kobayashi M; Adachi S; Izawa N; Noguchi Y; Nakatsu S; Sato Y; Takagi R; Itoh F
    Nihon Shokakibyo Gakkai Zasshi; 2010 Mar; 107(3):396-406. PubMed ID: 20203443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of gemcitabine and cisplatin combination chemotherapy versus gemcitabine alone for pancreatic cancer.
    Huang D; Fang J; Luo G
    J Cancer Res Ther; 2016 Oct; 12(Supplement):104-108. PubMed ID: 27721265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gemcitabine doublets in advanced pancreatic cancer: should we move on?
    Rocha Lima CM; Flores AM
    J Clin Oncol; 2006 Jan; 24(3):327-9. PubMed ID: 16344312
    [No Abstract]   [Full Text] [Related]  

  • 28. [Chemotherapy for pancreatic cancer].
    Sunamura M; Egawa S; Fukuyama S; Motoi F; Takeda K; Akada M; Ottomo S; Abe H; Matsuno S
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1901-8. PubMed ID: 14650957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
    O'Neil BH; Scott AJ; Ma WW; Cohen SJ; Aisner DL; Menter AR; Tejani MA; Cho JK; Granfortuna J; Coveler L; Olowokure OO; Baranda JC; Cusnir M; Phillip P; Boles J; Nazemzadeh R; Rarick M; Cohen DJ; Radford J; Fehrenbacher L; Bajaj R; Bathini V; Fanta P; Berlin J; McRee AJ; Maguire R; Wilhelm F; Maniar M; Jimeno A; Gomes CL; Messersmith WA
    Ann Oncol; 2015 Sep; 26(9):1923-1929. PubMed ID: 26091808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.
    Poplin E; Feng Y; Berlin J; Rothenberg ML; Hochster H; Mitchell E; Alberts S; O'Dwyer P; Haller D; Catalano P; Cella D; Benson AB
    J Clin Oncol; 2009 Aug; 27(23):3778-85. PubMed ID: 19581537
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
    Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Practical prognostic index for survival in patients with unresectable pancreatic cancer treated with gemcitabine or S-1.
    Kurihara T; Kogo M; Ishii M; Yoneyama K; Kitamura K; Shimada K; Shimizu S; Yoshida H; Kiuchi Y
    Hepatogastroenterology; 2015; 62(138):478-84. PubMed ID: 25916086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine-based concurrent chemoradiotherapy versus chemotherapy alone in patients with locally advanced pancreatic cancer.
    Wang BH; Cao WM; Yu J; Wang XL
    Asian Pac J Cancer Prev; 2012; 13(5):2129-32. PubMed ID: 22901181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Meta-analysis on gemcitabine of fixed-dose rate infusion plus oxaliplatin as first-line therapy for advanced pancreatic cancer].
    Xie DR; Liang HL; Yang Q; Guo SS; Jiang ZM
    Ai Zheng; 2007 Aug; 26(8):895-9. PubMed ID: 17697555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prognostic factors in patients with advanced pancreatic cancer treated with gemcitabine chemotherapy: clinical characteristics of long-term survivors].
    An SG; Kim DU; Song GA; Jang AL
    Korean J Gastroenterol; 2014 Dec; 64(6):356-63. PubMed ID: 25530587
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer.
    Park JK; Ryu JK; Lee JK; Yoon WJ; Lee SH; Kim YT; Yoon YB
    Pancreas; 2006 Nov; 33(4):397-402. PubMed ID: 17079946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Concurrent radiotherapy and gemcitabine for unresectable pancreatic adenocarcinoma: impact of adjuvant chemotherapy on survival.
    Ogawa K; Ito Y; Hirokawa N; Shibuya K; Kokubo M; Ogo E; Shibuya H; Saito T; Onishi H; Karasawa K; Nemoto K; Nishimura Y;
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):559-65. PubMed ID: 22019243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Boeck S; Wilkowski R; Bruns CJ; Issels RD; Schulz C; Moosmann N; Laessig D; Haas M; Golf A; Heinemann V
    Oncology; 2007; 73(3-4):221-7. PubMed ID: 18424886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results of a retrospective analysis of gemcitabine as a second-line treatment after chemoradiotherapy and maintenance chemotherapy using 5-fluorouracil in patients with locally advanced pancreatic cancer.
    Taira K; Boku N; Fukutomi A; Onozawa Y; Hironaka S; Yoshino T; Yasui H; Yamazaki K; Taku K; Hashimoto T; Nishimura T
    J Gastroenterol; 2008; 43(11):875-80. PubMed ID: 19012041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine Compared With Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.
    Li D; Chen C; Zhou Y; Chen R; Fan X; Bi Z; Li Z; Liu Y
    Medicine (Baltimore); 2015 Sep; 94(35):e1345. PubMed ID: 26334891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.